Home > Browse Research > Life Sciences > Pharmaceuticals > Diseases & Conditions > Crohn's

Crohn's: market research reports

Crohn’s disease, also known as regional enteritis, is a chronic nonspecific inflammatory disorder of the bowel. The disorder may become exacerbated by stress. Many theories have been suggested about the possible causes of Crohn’s disease and some recent studies are exploring the immunologic mechanisms as possible etiologic factors. Crohn’s disease has a prevalence of about 1.5 million in the United States and up to 4 million worldwide.

There is no known medical or surgical cure for Crohn's disease; treatments attempt to control symptoms, maintain remission, and prevent relapse.

Crohn’s disease can affect both the small and large intestines, and the areas of inflamed tissue are often separated by normal tissue. The lesions of Crohn’s disease are granulomatous ulcers that may involve deeper structures. The ulcers may perforate and form fistulas. Scar tissue may lead to intestinal obstruction. The loss of absorptive capability in Crohn’s disease leads to anorexia, weight loss, malaise, fluid loss, hypokalemia from loss of potassium-rich intestinal secretions, and hypoproteinemia from loss of protein through the damaged intestinal epithelium.

Crohn's market research reports and industry analysis

Crohn's Disease – Pipeline Review, H1 2013 2/28/2013 \| published by: Global Markets Direct ... Crohn's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Crohn's Disease. Crohn's Disease - Pipeline Review, Half Year is ... \| read more...	$2,000.00
EpiCast Report: Crohn’s Disease Epidemiology Forecast to 2022 1/31/2013 \| published by: GlobalData ... incidence rates for Crohn’s disease vary between 0.3 cases and 16.5 cases per 100,000 population, possibly indicative of an environmental influence in disease etiology (Economou et al., 2009). In the 10 major markets (the US, ... \| read more...	$3,995.00
Therapies and Biomarkers for Inflammatory Bowel Disease 1/1/2013 \| published by: BCC Research ... 2012, and projections of compound annual growth rates (CAGRs) through 2017 Discussion of the types of IBD, including Crohn's disease, ulcerative colitis, and other (ischemic, diversionary, Bechet's) Examination of the types of IBD diagnostics, such ... \| read more...	$5,450.00
Disease and Therapy Review: Crohn's Disease 11/5/2012 \| published by: Timely Data Resources, Inc. ... overview of treatment. Dosing and treatment cost information is provided for various treatment types and for medication. General information on the Crohn's Disease market, as well as sales of leading drugs and therapies are provided. \| read more...	$995.00
ChartTrends®: Crohn's Disease (US) 2012 9/26/2012 \| published by: Decision Resources ... audits are completed by 200+ physicians who submit between three and seven audits each. ChartTrends are syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. ... \| read more...	$15,000.00
Positioning of Current Biologics for Crohn’s Disease and Ulcerative Colitis: Physician and Payer Insight into Market Access Drivers in China and South Korea 9/12/2012 \| published by: Decision Resources ... of biologics has become more generous in recent years, as evidence for the efficacy of the TNF-a inhibitors has accumulated. In China, Remicade, the first biological agent approved for CD has been added to several ... \| read more...	$10,000.00
How Will Reimbursement Decisions for Novel Biologics and Biosimilars Impact Prescribing in the Dynamic Markets for Crohn’s Disease and Ulcerative Colitis? 8/28/2012 \| published by: Decision Resources ... marketed biologic. In both CD and UC, Janssen Biotech’s Remicade (infliximab) continues to dominate the U.S. market and stand as the therapy to beat for agents positioned in the segment of the market for patients ... \| read more...	$10,000.00
PatientTrends®: Crohn's Disease 2012 7/2/2012 \| published by: Decision Resources ... look at what drives patients’ satisfaction with their current crohn’s disease (CD) treatment, especially with regards to biologics, and identify what treatment attributes are most likely to prompt a patient to request a switch to ... \| read more...	$10,000.00
Crohn’s Disease: Gastroenterologists Look for Therapies with Enhanced Safety for Moderate to Severe Patients 3/12/2012 \| published by: Decision Resources ... CD, several pharmacological therapies are used to manage its symptoms, acutely and in the maintenance setting. The most potent of these therapies are the tumor necrosis factor-alpha (TNF-a) inhibitors. However, TNF-a inhibitors are associated with ... \| read more...	$10,000.00
TreatmentTrends®: Biologics in Crohn's Disease (US) 2012 2/29/2012 \| published by: Decision Resources ... market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, and sales force performance. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| read more...	$15,000.00
Crohn’s Disease Global Clinical Trials Review, H1, 2012 2/20/2012 \| published by: GlobalData ... and data relating to the clinical trials on Crohn’s Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ... \| read more...	$1,000.00
Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 12/19/2011 \| published by: GlobalData ... The report is an essential source of information and analysis on the global Crohn’s Disease Therapeutics market. The report identifies the key trends shaping and driving the global Crohn’s Disease Therapeutics market. The report also ... \| read more...	$3,500.00
Special Report: Current Treatments, Unmet Needs, and Opportunities in Treating Pediatric Crohn’s Disease 11/1/2011 \| published by: Decision Resources ... current treatment. With only one approved therapy for children-Janssen Biotech/Merck's Remicade (infliximab)-this market presents a reasonable opportunity for drug developers. Questions Answered Pediatric CD is a rare disorder. What is the total diagnosed prevalent population ... \| read more...	$9,200.00
Crohn's Disease - Pipeline Review, H2 2011 9/28/2011 \| published by: Global Markets Direct ... for Crohn's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Crohn's Disease. 'Crohn's Disease - Pipeline Review, H2 2011' ... \| read more...	$500.00
Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth 9/1/2011 \| published by: GBI Research ... Show Strongest Growth” provides in-depth analysis of the drivers and barriers that affect the global gastrointestinal disorder therapeutics market. The report analyzes the markets for gastrointestinal disorder therapeutics in the US, the top five countries ... \| read more...	$3,500.00
Crohn's Disease Global Clinical Trials Review, Q2, 2011 6/3/2011 \| published by: GlobalData ... and data relating to the clinical trials on Crohn’s Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ... \| read more...	$1,000.00
Autoimmune Diseases: Pipelines for Crohn's Disease, Multiple Sclerosis and Rheumatoid Arthritis 6/1/2011 \| published by: CHI Insight Pharma Reports ... targets are actively being investigated and what new targets are coming forward? Who has candidates in active Phase III and Phase II clinical trials? What does the overall target activity map, from launched drug to ... \| read more...	$795.00
Crohn's Disease Therapy Area Pipeline Report 3/14/2011 \| published by: Life Science Analytics (LSA) ... as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, ... \| read more...	$1,495.00
Crohns Disease - Pipeline Review, Q1 2011 2/28/2011 \| published by: Global Markets Direct ... for Crohns Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Crohns Disease. 'Crohns Disease - Pipeline Review, Q1 2011' ... \| read more...	$500.00
Crohn's Disease Therapy Pipeline Report 1/6/2011 \| published by: Life Science Analytics (LSA) ... drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user ... \| read more...	$1,495.00
Disease and Therapy Review: Crohn's Disease 12/26/2010 \| published by: Timely Data Resources, Inc. ... is provided for various treatment types and for medication. General information on the Crohn's Disease market, as well as sales of leading drugs and therapies are provided. Please note, this file is delivered as a ... \| read more...	$995.00
Crohns Disease - Pipeline Review, Q4 2010 12/8/2010 \| published by: Global Markets Direct ... Crohns Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Crohns Disease. “Crohns Disease-Pipeline Review 2010, Q4 2010” is built ... \| read more...	$500.00
Inflammatory Bowel Disease Market Forecast 8/5/2010 \| published by: Datamonitor ... major markets. Reasons to Purchase Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world Understand IBD market trends and assess the impact of ... \| read more...	$15,200.00
Pipeline Insight: Inflammatory Bowel Disease - Varied drug targets to broaden future therapy options 7/6/2010 \| published by: Datamonitor ... over $1 billion into a market projected to reach up to $5.7 billion by 2019 and offer more therapy choice to specific patient groups. Scope Segmentation and analysis of products across all stages of the ... \| read more...	$11,400.00
Gastrointestinal Disorder Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets 6/15/2010 \| published by: GBI Research ... Growth in Crohn's Disease and Irritable Bowel Syndrome Markets”, provides in-depth analysis of the unmet needs, drivers and barriers that affect the global gastrointestinal disorder therapeutics market. It analyzes the markets for gastrointestinal disorder therapeutics ... \| read more...	$3,500.00

< prev 1 2 next >